Login
Sangamo Therapeutics NASDAQ: SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
| Name | Sangamo Therapeutics |
| Ticker | SGMO |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 15.75 |
| 52W Low/High | 5.05 / 18.18 |
| Market cap | 2.2 B |
| 1Y Total Return |
88.17%
Strong |
| 1Y Volatility |
89.02%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
Details
| Ticker | SGMO |
| Name | Sangamo Therapeutics |
| ISIN | US8006771062 |
| CUSIP | 800677106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
| Close Price | 15.75 |
| 52W Low/High | 5.05 / 18.18 |
| Market cap | 2.2 B |
| 1Y Total Return |
88.17%
Strong |
| 1Y Volatility |
89.02%
High Risk |
| Beta | 1.10 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -51.5% |
| Cash from Op. / Cur. Liabilities | 1.24 |
| Diluted Earnings / Share | -0.59 |
| ROE | - |
| ROIC | -14.8% |
| Price / Revenue | 15.1 |
| Price / Book | 4.3 |
| Price / CF | 14.5 |
| Current Ratio | 5.7 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.07 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
147
|
74
|
71
|
32
|
20
|
45
|
|
| Gross Profit |
147
|
74
|
71
|
32
|
20
|
45
|
|
| R&D |
167
|
141
|
101
|
60
|
72
|
62
|
|
| EBITDA |
-59
|
-111
|
-61
|
-50
|
-77
|
-34
|
|
| Operating Income |
-85
|
-127
|
-70
|
-52
|
-78
|
-36
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
141
|
116
|
102
|
84
|
71
|
70
|
|
| EPS exc. Extra |
-0.59
|
-1.09
|
-0.68
|
-0.69
|
-1.08
|
-0.44
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
964
|
640
|
607
|
270
|
165
|
233
|
|
| Cash, Eq & Invt ShortTerm |
650
|
357
|
459
|
237
|
146
|
219
|
|
| Total Current Assets |
700
|
384
|
468
|
242
|
149
|
228
|
|
| Total Non-Current Assets |
263
|
256
|
138
|
27
|
16
|
5
|
|
| Intangibles |
97
|
90
|
2
|
2
|
2
|
2
|
|
| Total Liabilities |
443
|
221
|
227
|
83
|
21
|
29
|
|
| Total Current Liabilities |
124
|
81
|
74
|
43
|
14
|
22
|
|
| Long Term Debt |
319
|
140
|
153
|
40
|
7
|
7
|
|
| Shareholder equity |
521
|
419
|
380
|
187
|
144
|
204
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
153
|
-164
|
60
|
16
|
-63
|
-27
|
|
| Depreciation |
17
|
7
|
2
|
1
|
1
|
1
|
|
| Cash from Investing |
-158
|
19
|
-213
|
-99
|
57
|
32
|
|
| Capex |
17
|
42
|
16
|
3
|
2
|
2
|
|
| Cash from Financing |
147
|
142
|
242
|
85
|
0
|
19
|
|
| Stock Issued |
148
|
143
|
243
|
86
|
1
|
9
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-215
|
15
|
-268
|
-118
|
-5
|
-62
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.7
|
4.8
|
6.3
|
5.6
|
10.7
|
10.3
|
|
| Financial Leverage D/E |
0.07
|
0.10
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-14.8%
|
-25.3%
|
-18.2%
|
-31.9%
|
-49.5%
|
-15.5%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available